Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Uterine Neoplasms|Uterine Cervical Neoplasms|Biliary Tract Neoplasms|Urologic Neoplasms|Carcinoma, Non-Small-Cell Lung|HER2 Mutations Breast Neoplasms
Interventions: DRUG: tucatinib|DRUG: trastuzumab|DRUG: fulvestrant
Sponsor: Seagen Inc.